ClinicalTrials.Veeva
Menu

Find clinical trials for Lung Cancer in Hanyang, Seoul

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Non-Small-Cell Lung Carcinoma
Small Cell Lung Carcinoma
Cancer
Colorectal Cancer
Neoplasm Metastasis
Breast Cancer
Squamous Cell Carcinoma of Head and Neck

Lung Cancer trials near Hanyang, Seoul, KOR:

Study to Investigate Petosemtamab in Adults With Metastatic Non-Small Cell Lung Cancer

Pembrolizumab in first line patients with squamous non-small cell lung cancer and non-squamous non-small cell lung cancer...

Enrolling
Lung Cancer - Non Small Cell Squamous
Lung Cancer - Non Small Cell Non-Squamous
Combination Product: Petosemtamab + Pembrolizumab

Phase 2

Merus B.V.

Seoul, South Korea and 23 other locations

Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer (ARC-10)

to evaluate zimberelimab (AB122) combined with domvanalimab (AB154) in front-line, PD-L1-high, locally advanced or metastatic Non-Small Cell Lung...

Active, not recruiting
Squamous Non Small Cell Lung Cancer
Nonsquamous Non Small Cell Lung Cancer
Drug: Pembrolizumab
Drug: Pemetrexed

Phase 2

Arcus Biosciences
Arcus Biosciences

Seoul, South Korea and 45 other locations

Locations recently updated

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic non-small-cell lung...

Enrolling
Metastatic Non Small Cell Lung Cancer
Biological: LN-145

Phase 2

Iovance Biotherapeutics

Seoul, South Korea and 71 other locations

Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer (KontRASt-02)

to docetaxel in participants with advanced non-small cell lung cancer (NSCLC) harboring a KRAS G12C mutation who have been previous...

Active, not recruiting
Non-Small Cell Lung Cancer
Drug: JDQ443
Drug: docetaxel

Phase 3

Novartis
Novartis

Seongnam-si, Gyeonggi-do, South Korea and 50 other locations

Study With Various Immunotherapy Treatments in Participants With Lung Cancer (EDGE-Lung)

The purpose of this study is to assess the objective response rate (ORR) of immunotherapy-based combination therapy and to assess the safety and tole...

Active, not recruiting
Advanced Non-Small Cell Lung Cancer
Drug: Docetaxel
Drug: Zimberelimab

Phase 2

Gilead Sciences
Gilead Sciences

Seoul, South Korea and 52 other locations

Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)

with previously treated advanced or metastatic non-small cell lung cancer (NSCLC) with or without actionable genomic alterations....

Active, not recruiting
Non-small Cell Lung Cancer
Drug: Docetaxel
Drug: DS-1062a

Phase 3

Daiichi Sankyo
Daiichi Sankyo

Seoul, South Korea and 210 other locations

ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer

over time. The third main question is to see if ELVN-002 works to shrink cancers that have HER2 genetic abnormalities, particularly non-sma ...

Active, not recruiting
HER2 Mutant Non-small Cell Lung Cancer
HER2-positive Metastatic Breast Cancer
Drug: ELVN-002
Drug: Trastuzumab emtansine

Phase 1

Enliven Therapeutics

Seoul, South Korea and 38 other locations

Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy

This is a Phase II, multi-site, open-label, parallel group study in participants with untreated extended-stage small-cell lung cancer...

Active, not recruiting
Small-cell Lung Cancer
Extensive-stage Small-cell Lung Cancer
Drug: Paclitaxel
Drug: BNT327 Dose Level 2 (DL2)

Phase 2

BioNTech
BioNTech

Seoul, South Korea and 64 other locations

HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

This study is designed to evaluate the antitumor activity of patritumab deruxtecan in participants with metastatic or locally advanced NSCLC with an...

Active, not recruiting
Non-Small Cell Lung Cancer Metastatic
Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
Drug: Patritumab Deruxtecan (Fixed dose)
Drug: Patritumab Deruxtecan (Up-Titration)

Phase 2

Daiichi Sankyo
Daiichi Sankyo

Seoul, South Korea and 123 other locations

A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)

The study is focused on patients who have advanced non-small cell lung cancer (NSCLC).The aims of this study are to see how safe an...

Active, not recruiting
Advanced Non-Small Cell Lung Cancer
Drug: Cemiplimab
Drug: BNT116

Phase 2

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Seoul, South Korea and 52 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2026 Veeva Systems